Irish Regulator Prepares For Brexit-Related Problems, Offers To Take On More EU Work
Executive Summary
Ireland’s healthcare products regulator HPRA says it is taking steps to deal with possible supply interruptions as a result of Brexit, and that it is ready to assume some of the regulatory workload that will result from the European Medicines Agency’s departure from the UK. A stakeholder workshop will be held at the end of August where pharma firms and distributors will be able to discuss Brexit-related concerns with the regulator.
You may also be interested in...
Irish Brexit Event A Chance For Originator And Biosimilar Firms To Air Their Concerns
A stakeholder event being organized by the Irish regulatory body, the HPRA, will hear views on the implications and risks of Brexit from associations representing the originator and generic/biosimilar industries, as well as the head of the HPRA’s task force on Brexit.
EU Member States Taking New Steps To Tackle Drug Shortages
The EU Heads of Medicines Agencies has outlined some of the recent initiatives taken by the member states to deal with medicines shortages, including a new Dutch center and a member state coordinating initiative by the Irish regulator.
Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones
The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.